Pharmaceutical logistics is no longer a silent operation running behind the healthcare industry. In a global market marked by operational disruptions, route restrictions, cost pressures, increasingly stringent regulatory requirements, and a worldwide uncertainty that can alter transit times, availability, and transport conditions, moving medicines, vaccines, biological products, reagents, and sensitive supplies now demands a level of planning far more precise than in other industries.
The difference lies in the impact. A delay, a temperature deviation, a documentation failure, or poor coordination at final delivery does not only affect a commercial operation. It can also compromise treatments, the supply of medical centers, laboratory continuity, and the ability of healthcare systems to respond to critical needs — making logistics a key element in risk management, operational continuity, and people’s quality of life.
For Elizabeth Poblete, Pharmaceutical Logistics Specialist & Commercial Executive at International Line, the industry is facing an inflection point.
“In pharmaceutical logistics, moving cargo from point A to point B is not enough. What matters is ensuring that the product maintains its conditions, arrives on time, and meets the standards required by an industry directly linked to people’s health and quality of life,” she emphasized.
A decision that no longer depends on transport alone
In pharma, choosing between air, sea, or multimodal transport cannot be driven solely by cost, speed, or space availability. Each shipment must be analyzed based on the product’s criticality, thermal sensitivity, shelf life, documentation requirements, urgency, operational risk, and final delivery conditions — especially when healthcare supply depends on an end-to-end coordinated chain.
Air transport continues to play a key role for urgent cargo, high-value products, shipments with limited shelf life, or situations where transit time can define supply continuity. However, airport congestion, route changes, limited availability, fare fluctuations, and international disruptions require earlier planning and a move away from relying on a single alternative.
Sea transport, on the other hand, is gaining ground for more stable pharmaceutical products, planned shipments, or larger volumes that can travel under controlled conditions. Refrigerated containers, temperature monitoring, evaluated routes, and coordinated documentation make this option viable — provided there is technical validation and rigorous risk management.
Cold chain, traceability, and document control
The central question, then, is not whether a shipment should travel by air or sea, but which solution best protects product integrity and guarantees supply continuity in an increasingly unpredictable international environment. In an industry directly linked to patients, hospitals, laboratories, and medical centers, logistics becomes a strategic decision for companies, operators, and healthcare systems alike.
One of the most sensitive points is the cold chain. According to Poblete, “maintaining proper conditions throughout the entire logistics process protects the quality, safety, and efficacy of products. This requires monitoring, control, documentation, clear protocols, and constant communication among all parties involved.”
This requirement demands connecting the entire chain: origin, documentation, international transport, storage, domestic distribution, and final delivery. In pharmaceutical products, a deviation can occur at any stage — which is why traceability, continuous visibility, and communication between actors are just as important as the chosen mode of transport.
Last-mile delivery also defines success
Although attention often focuses on international transport, Poblete warns that the process does not end when the cargo arrives in the destination country. Pharmaceutical last-mile delivery must also meet standards of temperature control, traceability, documentation, and operational oversight.
“The logistics chain does not end when the cargo arrives in the destination country, but when it is delivered to the end customer under the required conditions,” Poblete states.
This stage requires appropriate vehicles, monitoring, control protocols, and coordination with the recipient. For medicines, vaccines, clinical samples, or sensitive supplies, final delivery cannot be treated as an afterthought — it is an essential part of the complete logistics strategy.
Anticipating rather than reacting
Global uncertainty has pushed pharma logistics from a reactive model toward strategic planning. If routes can change, transit times extend, costs vary, and operational conditions shift from one week to the next, companies need alternative scenarios, up-to-date information, specialized operators, and contingency plans defined before a problem arises.
For this reason, Poblete stresses that “in pharmaceutical logistics, anticipating is just as important as reacting correctly to a deviation.”
In this transition, logistics is beginning to occupy a more visible place in discussions around innovation, healthcare, supply, the Chilean economy, and companies’ capacity to respond to increasingly complex global environments. It is no longer just about reaching the destination — it is about doing so under the right conditions, with evidence, control, traceability, and coordination among all actors in the chain.
A logistics operation that is now part of the healthcare strategy
The challenge for laboratories, drugstores, importers, logistics operators, and companies linked to the medical sector will be to move toward more resilient, traceable, and coordinated supply chains — ones where risk management, cold chain integrity, last-mile delivery, and contingency planning cease to be isolated operational elements and become part of strategic planning.
In an environment of global uncertainty, the ability to anticipate scenarios will be essential to protect healthcare supply, prevent disruptions, and respond to an industry directly connected to people’s health and quality of life.
From this perspective, pharmaceutical logistics also presents a challenge for the Chilean economy, public policy, innovation, and territorial development — particularly when it comes to ensuring timely access to medicines, vaccines, biological products, and sensitive supplies across different regions of the country. For the sector, the new standard will not simply be reaching the destination, but doing so with evidence, traceability, temperature control, coordination among actors, and the capacity to respond in an increasingly uncertain global market.
